The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

VISCHER

AESCHENVORSTADT 4, 4010 BASEL, SWITZERLAND
Tel:
Work +41 58 211 33 00
Fax:
Fax +41 58 211 33 10
Email:
Web:
www.vischer.com
Basel, ZURICH

Dr Matthias Staehelin

Tel:
Work +41 58 211 33 53
Email:
VISCHER

Work Department

Private Equity, Mergers and Acquisitions, Capital Market Transactions, Restructuring and Establishment of Companies, Health Care Law.

Position

Partner. Co-Head Corporate Practice Groupd and Co-Head Life Sciences Practice Group

Career

Associate with the New York office of Cravath Swaine & Moore (1994) General reporter of the AIJA-Seminar on Cross Border M&A, New York (2000).

Languages

German, English, French.

Member

Bio Valley Association (President), BioBac BioValley Business Angel Club (Treasurer)

Education

University of Basel (lic. iur., 1990; Dr. iur., 1993) College of Europe, Bruges (Master of Advanced European Studies, 1992/Diplome des Hautes Etudes Europeennes, 1991) College: Internationalisierung des Privatrechts Freiburg i.B. (1992/93).


Switzerland

Capital markets

Within: Capital markets

Derivatives, securities listings, IPOs, bond issues and fintech products constitute the core areas of advice at VISCHER. Markus Guggenbühl assists UK-based Elliott Advisors on Swiss securities laws, takeover and disclosure rules in connection with several matters, while Robert Bernet advised Openlimit Holding during its authorised investment capital increase; its shares are traded on the Frankfurt Stock Exchange. Matthias Staehelin advised Crispr Therapeutics on a $130m public offering of shares on Nasdaq.

[back to top]

Commercial, corporate and M&A

Within: Commercial, corporate and M&A

VISCHER has 'a strong position in the Basel market' and 'can assist very well in corporate transactions', with a particular focus on mid-market M&A and private equity deals, as well as Chinese inbound and outbound transactions. Jürg Luginbühl and the 'very responsive' Robert Bernet 'align teams according to the size of the transaction' and provide 'pragmatic solutions while maintaining reasonable hourly rates'. Recent highlights include handling Dutch client Lundbeck's €905m acquisition of the entire share capital in Prexton Therapeutics, as well as advising GreatStar Hangzhou Industrial on the purchase of Lista. Life sciences and IT specialist Matthias Staehelin is the another key contact.

[back to top]

Healthcare and life sciences

Within: Healthcare and life sciences

VISCHER is renowned for its expertise in corporate, commercial, transactional, regulatory and patent-related healthcare and biotech matters. Matthias Staehelin assisted Medartis with its initial public offering on the SIX Swiss Exchange, while Stefan Kohler acted for Novo Nordisk Pharma in its appeal against a pricing decision made by the Swiss Federal Office of Public Health concerning the client's type-two diabetes product. Christian Wyss advised Lundbeck on its €905m acquisition of Prexton Therapeutics.

[back to top]


Back to index

Legal Developments by:
VISCHER

  • Capital Contribution Principle: Meaning and Proceedings

    On January 1, 2011, the Swiss tax law capital contribution principle (CCP) enters into force - with far reaching consequences for companies, their owners, board members and tax advisors. A few days ago the Federal Tax Administration (FTA) published a Circular Letter on this change of law.
    - VISCHER

Legal Developments in Switzerland

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to